Nuclear Medicine Market worth $9.4 billion

CHICAGO, May 5, 2023 /PRNewswire/ — The nuclear medication market is poised for substantial development in the future, driven by the increasing occurrence of cancer and persistent illness that need sophisticated diagnostic and treatment choices. Advancements in imaging innovation, such as hybrid imaging and PET-CT scans, are likewise sustaining need for nuclear medication. Additionally, there is a concentrate on establishing radiopharmaceuticals and theragnostic that can target particular illness and provide treatments straight to impacted locations. Despite possible difficulties such as the high cost of equipment and the lack of qualified specialists, the outlook for the nuclear medication market is positive, and it is anticipated to continue to innovate and enhance client care in the coming years.

Nuclear Medicine Market in regards to profits was approximated to be worth $5.5 billion in 2023 and is poised to reach $9.4 billion by 2028, growing at a CAGR of 11.3% from 2023 to 2028 according to a brand-new report by MarketsandMarkets™. The nuclear medication market is generally driven by aspects such as increasing occurrence and frequency of target illness and require for adoption of nuclear medication for early medical diagnosis of illness. However, medical facility budget plan cuts and high equipment costs have actually made it tough for an area of end users to go with nuclear medication are challenging the development of this market.

Download an Illustrative introduction: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=417

Browse thorough TOC on “Nuclear Medicine Market”

449 – Tables
39 – Figures
359 – Pages

Nuclear Medicine Market Scope:

The diagnostic nuclear medication sector is anticipated to hold the biggest market share throughout the projection duration.

On the basis of type, the nuclear medication market is segmented into diagnostic and healing nuclear medication. The diagnostic nuclear medication sector is additional classified as SPECT and animal radiopharmaceuticals, while the healing nuclear medication sector is additional divided into beta emitters, alpha emitters, and brachytherapy isotopes. The diagnostic nuclear medication sector is anticipated to holds the biggest share of the nuclear medication market throughout projection duration. The increasing frequency of cancer and heart diseases, and improvements in radiotracers are a few of the crucial aspects driving the development of this sector.

Story continues

The diagnostic treatment sector is predicted to hold the biggest market share throughout the projection duration.

On the basis of procedural volume, the nuclear medication market is segmented into diagnostic and healing treatments. The diagnostic treatment sector is additional classified as SPECT and animal treatments. The diagnostic treatments represented the biggest share, in the nuclear medication market.  The big share of this sector can be credited to the diagnostic radioisotopes discovering broader need and usage as compared to healing radioisotopes.

The diagnostic application sector is anticipated to represent the biggest share of the nuclear medication application market in 2022.

On the basis of application, the nuclear medication market is segmented into diagnostic and healing applications. The diagnostic application sector is additional classified as SPECT and animal applications, while the healing nuclear medication sector is additional divided into endocrine growths, thyroid signs, bone transition, lymphoma, other healing applications. The diagnostic application sector is anticipated to represent the biggest share of the nuclear medication market. The increasing need for SPECT medical diagnosis owing to the increasing need for minimally intrusive surgical treatments and targeted radiotherapy is the significant aspect driving the adoption of the diagnostic application utilizing nuclear medication.

North America represented the biggest share for gamers running in the nuclear medication market in 2022

On the basis of area, the nuclear medication market is bifurcated into North America, Europe, Asia Pacific, and the Rest of the World (RoW). North America holds the biggest share of the nuclear medication market in 2022. This can be credited to the increasing rise of geriatric population, growing requirement of nuclear medication in the early medical diagnosis of illness, innovation development for radioisotope production, federal government financing, and crucial gamers in this area are likewise urging the nuclear medication market in the area.

Inquiry Before Buying: https://www.marketsandmarkets.com/Enquiry_Before_BuyingNew.asp?id=417

Nuclear Medicine Market Dynamics:

Drivers:

1. Increasing occurrence and frequency of target conditions

2. Development of alpha-radioimmunotherapy-based targeted cancer treatments

3. Initiatives to lower need and supply space of Mo-99

Restraints:

1. Short half-life of radiopharmaceuticals

Opportunities:

1. Use of radiopharmaceuticals in neurological applications

2. Growth opportunities in emerging economies

Challenges:

1. Hospital budget plan cuts and high equipment expenses

Key Market Players:

The nuclear medication market is extremely combined. Some of the significant gamers running in this market consist of GE HealthCare (United States), Cardinal Health (United States), Curium (France),Bayer AG (Germany), Lantheus Holdings, Inc.(United States), Bracco Imaging S.p.A. (Italy), PharmaLogic Holdings Corp. (United States), Eczacibasi-Monrol Nuclear Products (Turkey), NTP Radioisotopes SOC Ltd (South Africa), Nordion Inc.(Canada), Advanced Accelerator Applications (France), NorthStar Medical Radioisotopes (United States), Eckert & Ziegler (Germany), Isotope JSC (Russia), Siemens Healthineers (Germany), Jubilant DraxImage,Inc. (Canada).

Get 10% Free Customization on this Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=417

Recent Developments:

• In January 2023, NorthStar Medical Radioisotopes (United States) accomplished a significant turning point beforehand its brand-new innovation for non-uranium-based production of the vital medical radioisotope, molybdenum-99 (Mo-99).

• In November 2022, Curium (France) revealed that the United States Food and Drug Administration (FDA) authorized DaTscan (Ioflupane I 123 Injection) to help in examining adult clients with thought Parkinsonian Syndromes.

• In October 2022, Blue Earth Diagnostics (UK) signed a data-sharing contract with Siemens Healthineers (Germany) and the University Hospital of the Technical University of Munich (TUM) for 18F-rhPSMA-7.3, an investigational animal imaging representative, to support AI-based algorithms advancement.

• In January 2021, Advanced Accelerator Applications (France) signed a multi-year unique supply contract for lutetium-177 with the University of Missouri Research Reactor (MURR). Through this contract, MURR will provide AAA with GMP-quality lutetium-177 chloride, the precursor for establishing Lutathera and other Lu-177-based rehabs.

Nuclear Medicine Market Advantages:

• Accurate medical diagnosis: nuclear medication enables extremely precise medical diagnosis of numerous illness and conditions, consisting of cancer, cardiovascular disease, and neurological conditions. This is since it makes it possible for imaging and practical evaluation at a molecular level, supplying more accurate info about the illness.

• Personalized treatment: Radiopharmaceuticals utilized in nuclear medication can be personalized to target particular tissues or cells, making it possible for individualized treatment for clients. This method can enhance treatment results and lower negative effects.

• Minimally intrusive: nuclear medication treatments are minimally intrusive and need just percentages of radioactive products. This suggests that they are usually more secure and less intrusive than surgeries.

• Early detection: nuclear medication can find illness and conditions at an early phase, prior to signs appear. This can cause earlier treatment and much better results.

• Non-intrusive: Nuclear medication treatments are usually non-invasive, which suggests they do not need cuts or other intrusive strategies. This can cause faster healing times and lower danger of issues.

Nuclear Medicine Market – Report Highlights:

The upgraded variation of the report covers the historic market for the nuclear medication market for the years 2021 and 2022, the approximated market for 2023, and the projection for 2028, together with CAGR from 2023 to 2028.

UPGRADED MARKET INTRODUCTION:

• The existing edition of the report covers regulative bodies, federal government companies, and other companies, market patterns, rates analysis, crucial conferences & occasions, pipeline analysis, and crucial stakeholders & purchasing requirements in the market introduction chapter.

ADDITION OF END USER:

UPGRADED COMPETITIVE LANDSCAPE CHAPTER:

• The competitive landscape chapter has actually been upgraded with the business examination quadrant (DIVE Matrix), business examination quadrant for start-ups, footprint of nuclear medicine/radiopharmaceuticals market by type, and geographical evaluation of the leading market gamers.

• The competitive landscape likewise consists of the upgraded techniques embraced by crucial gamers, a profits share analysis of the leading market gamers, along with competitive scenarios and patterns area.

BUSINESS PROFILES:

• Company profiles provide a look of the crucial gamers in the market with regard to business summaries, financials, item offerings, and recent advancements. One extra business profile has actually been included (an overall of 25 business profiled).

UPGRADED FINANCIAL INFORMATION/PRODUCT PORTFOLIOS OF PLAYERS:

• The brand-new edition of the report offers upgraded monetary info in the context of the nuclear medication market up until 2022 for each noted business in a visual representation in a single diagram (rather of several tables). This will quickly help examine today status of profiled business in regards to their monetary strength, crucial revenue-generating country/region, business sector focus in regards to the greatest revenue-generating sector, and financial investments in R&D activities.

UPGRADED MARKET ADVANCEMENTS OF PROFILED PLAYERS:

Recent advancements are essential to comprehend the marketplace pattern and development techniques embraced by gamers in the international nuclear medication market space. The existing edition of this report offers upgraded advancements of profiled gamers from January 2019 to March 2023, suggesting an extension of the previous variation. Partnerships, partnerships, contracts, item approval & improvements, growths, and acquisitions have actually been the primary development techniques embraced by the market gamers in this duration.

ADDITION OF ECONOMIC CRISIS EFFECT:

• The existing edition of the report includes the effect of the economic crisis on the nuclear medicine/radiopharmaceuticals market.

• An area on the effect of the economic crisis on all local markets, such as North America, Asia Pacific, Europe, and Rest of the World have actually been consisted of.

Related Reports:

Radiation Detection Monitoring Safety Market – Global Forecasts to 2027

Surgical Robots Market – Global Forecasts to 2027

Electroceuticals Market – Global Forecasts to 2026

Diagnostic Imaging Market – Global Forecasts to 2026

Nuclear Imaging Equipment Market – Global Forecasts to 2025

About MarketsandMarkets™:

MarketsandMarkets™ is a blue ocean option in development consulting and program management, leveraging a man-machine offering to drive supernormal development for progressive companies in the B2B space. We have the largest lens on emerging innovations, making us competent in co-creating supernormal development for customers.

The B2B economy is seeing the introduction of $25 trillion of brand-new profits streams that are replacing existing profits streams in this years alone. We deal with customers on development programs, assisting them monetize this $25 trillion chance through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.

Built on the ‘OFFER Growth’ concept, we deal with numerous Forbes Global 2000 B2B business – assisting them remain appropriate in a disruptive environment. Our insights and techniques are formed by our market professionals, advanced AI-powered Market Intelligence Cloud, and years of research study. The KnowledgeStore™ (our Market Intelligence Cloud) incorporates our research study, helps with an analysis of affiliations through a set of applications, assisting customers take a look at the whole environment and comprehend the profits moves taking place in their market.

To discover more, check out www.MarketsandMarkets™.com or follow us on Twitter, LinkedIn and Facebook.

Contact:
Mr. Aashish Mehra
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
U.S.A.: +1-888-600-6441
Email: [email protected]
Research Insight: https://www.marketsandmarkets.com/ResearchInsight/radiopharmaceuticals-market.asp
Visit Our Website: https://www.marketsandmarkets.com/
Content Source: https://www.marketsandmarkets.com/PressReleases/radiopharmaceuticals.asp

Logo: https://mma.prnewswire.com/media/660509/MarketsandMarkets_Logo.jpg

View initial material: https://www.prnewswire.com/news-releases/nuclear-medicine-market-worth-9-4-billion–marketsandmarkets-301816917.html

SOURCE MarketsandMarkets